Every material Form 8-K PMV Pharmaceuticals, Inc. has filed with the SEC since August 31, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
PMV Pharmaceuticals appointed Dr. Matthew Eckler, a Principal at Samsara BioCapital, to its Board of Directors effective October 1, 2026. The filing describes a routine board addition with standard non-employee director compensation, and it notes the company plans to submit an NDA for accelerated approval of rezatapopt in the first quarter of 2027.
Dr. Eckler's board term expires at the 2029 Annual Meeting of Stockholders; appointment date October 1, 2026.
Annual cash retainer of $40,000 plus additional cash pay for committee service.
Initial stock option award for 84,000 shares; expected annual option for 42,000 shares at each annual meeting.
Company plans to submit an NDA for rezatapopt in platinum-resistant/refractory ovarian cancer in Q1 2027.
PMV Pharma agreed on August 31, 2026 to sell 22,055,000 shares and pre-funded warrants for 19,900,000 shares, each sold with a warrant, at a combined price of $1.21 per share, with warrants for 41,955,000 shares in total. The company estimates net proceeds of about $47.0 million and expects the offering to close on September 2, 2026. The warrants' exercise price can reset after an FDA decision accepting the rezatapopt New Drug Application, which could increase the number of shares issuable and add dilution for existing shareholders.
Offering includes 22,055,000 shares and pre-funded warrants for 19,900,000 shares, plus accompanying warrants for 41,955,000 shares, at a combined price of $1.21
Gross proceeds expected to be about $50.8 million; estimated net proceeds about $47.0 million; closing expected September 2, 2026
Warrants have a $1.21 initial exercise price and a five-year term; exercise price resets to the greater of 33% of the initial price or a VWAP-based level after the FDA NDA acceptance announcement for rezatapopt
Company believes proceeds plus existing cash will fund operations and capital expenditures into the first quarter of 2028, excluding any underwriters' option exercise
PMV Pharmaceuticals reported updated interim ovarian cancer data for rezatapopt from the Phase 2 pivotal portion of its PYNNACLE trial, with a 46% overall response rate among 76 evaluable patients. The company said recent FDA feedback supports submitting a new drug application for accelerated approval in platinum-resistant or refractory ovarian cancer in the first quarter of 2027, which sets a timeline for shareholders to track.
Overall response rate of 46% (35 of 76 patients) as of a May 14, 2026 data cutoff; median duration of response was 10.0 months
Company anticipates submitting an NDA for accelerated approval in the first quarter of 2027
Discontinuation due to treatment-related adverse events was 5%; full update on all Phase 2 cohorts planned for the fourth quarter of 2026 at a medical conference
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PMV Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →